NEW YORK (GenomeWeb News) – Synthetic Genomics and Integrated DNA Technologies today announced a deal to manufacture, market, and commercialize small synthetic gene products.
The deal, the terms of which were not disclosed, calls for the companies to construct custom, synthetic, double-stranded nucleic acids up to 5 kilobases. IDT will combine its expertise in custom oligonucleotide manufacturing with Synthetic Genomics' technology to assemble small gene constructs.
The collaboration is expected to result in "more affordable, efficient gene synthesis products that can be delivered more quickly to the synthetic biology community," Joe Walder, founder and CEO of IDT, said in a statement.
Craig Venter, founder and CEO of Synthetic Genomics, called the deal "a key component to advance our synthetic DNA business."
A few months ago Synthetic Genomics and Plenus announced the formation of a new company called Agradis to develop and commercialize products leveraging new genomics technologies.